Recombinant Human KIR3DL2/CD158k Fc Chimera Protein, CF

Recombinant Human KIR3DL2/CD158k Fc Chimera (Catalog #2878-KR)binds toMDA-MB-231 human breast cancer cells. The ED50 for this effect is0.06-0.36 μg/mL.

• Reactivity: Hu
• Applications: Binding Activity
• Format: Carrier-Free

Recombinant Human KIR3DL2/CD158k Fc Chimera Protein, CF Summary

• Details of Functionality: Measured by its ability to bind HLA on MDA‑MB‑231 human breast cancer cells. The ED₅₀ for this effect is 0.06-0.36 μg/mL.
• Source: Mouse myeloma cell line, NS0-derived human KIR3DL2/CD158k protein
  

  Human KIR3DL2 (Leu22-Leu339) Accession # P43630	IEGRMD	Human IgG1 (Pro100-Lys330)
  N-terminus		C-terminus

• Accession #: P43630
• N-terminal Sequence: Leu22
• Structure / Form: Disulfide-linked homodimer
• Protein/Peptide Type: Recombinant Proteins
• Gene: KIR3DL2
• Purity: >90%, by SDS-PAGE under reducing conditions and visualized by silver stain.
• Endotoxin Note: <1.0 EU per 1 μg of the protein by the LAL method.

Applications/Dilutions

• Theoretical MW: 61.4 kDa (monomer).
  Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.
• SDS-PAGE: 85-90 kDa, reducing conditions

Packaging, Storage & Formulations

• Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 3 months, -20 to -70 °C under sterile conditions after reconstitution.
• Buffer: Lyophilized from a 0.2 μm filtered solution in PBS.
• Purity: >90%, by SDS-PAGE under reducing conditions and visualized by silver stain.
• Reconstitution Instructions: Reconstitute at 100 μg/mL in sterile PBS.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for Recombinant Human KIR3DL2/CD158k Fc Chimera Protein, CF

• killer cell immunoglobulin-like receptor 3DL2
• CD158k
• CL-5
• killer cell immunoglobulin-like receptor, three domains, long cytoplasmic tail, 2
• KIR3DL2
• NKAT4
• NKAT-4
• NKAT4A
• NKAT4B
• p140

Background

KIR3DL2 (also known as 3DL2, p140, CD158k) is a type I transmembrane protein of the p70 family of killer cell Ig-like receptors (KIR). KIR are expressed on CD56^dim NK cells and T cell subsets where they participate in identifying normal and abnormal cells and regulating effector functions of the innate immune system (1 - 4). KIR are named for the number of Ig-like domains (2D or 3D) in the extracellular domain (ECD) and whether they have long or short (L, S) cytoplasmic tail. As with other inhibitory KIR, KIR3DL2 has two ITIM domains within its long tail (3). KIR3DL2 is diverse, with twelve alleles identified and as many as five single amino acid (aa) polymorphisms found in a single individual (4 - 6). Unlike most other KIR, gene transcripts of KIR3DL2 are expressed by all individuals (4). KIR3DL2 is present on the cell surface as a disulfide-linked homodimer of two 70 kDa, 434 aa subunits (4). KIR3DL2 has shown peptide-specific binding to some HLA-A antigens, including A3 and A11 (4, 7, 8). It also binds the abnormally folded HLA-B27 homodimer found in spondylarthritides, but not the normal heterodimer of HLA-B27 with beta 2-microglobulin (9, 10). NK and CD4⁺ T cells from patients with spondylarthritides show increased KIR3DL2⁺ expression and this may play a role in disease pathology (10). KIR3DL2 is also a marker for atypical mononuclear (Sezary) cells in the blood of patients with Sezary syndrome, an erythrodermic form of cutaneous T cell lymphoma (11). Human KIR3DL2 ECD shows 88 - 92% aa identity to KIR3DL2 of other primates. KIR receptors have no structural orthologs in non-primates, although mouse Ly-49 proteins are functional orthologs (3). KIR are highly related. The closest relative, KIR3DL1 shows 86% aa identity with KIR3DL2 within the ECD.

1. Colonna, M. and J. Samaridis (1995) Science 268:405.
2. Pende, D. et al. (1996) J. Exp. Med. 184:505.
3. Lanier, L. L. (2005) Annu. Rev. Immunol. 23:225.
4. Uhrberg, M. et al. (1997) Immunity 7:753.
5. Meenaugh, A. et al. (2004) Tissue Antigens 64:226.
6. Kwon, D. et al. (2000) Mol. Cells 10:54.
7. Dohring, C. et al. (1996) J. Immunol. 156:3098.
8. Hansasuta, P. et al. (2004) Eur. J. Immunol. 34:1673.
9. Kollnberger, S. et al. (2002) Arthritis Rheum. 46:2972.
10. Chan, A. T. et al. (2005) Arthritis Rheum. 52:3586.
11. Poszepczynska-Guigne, E. et al. (2004) J. Invest. Dermatol. 122:820.

Publications for KIR3DL2/CD158k (2878-KR)(2)

Publications using 2878-KR

• S Ryser, A Estellés, E Tenorio, LM Kauvar, ML Gishizky High affinity anti-TIM-3 and anti-KIR monoclonal antibodies cloned from healthy human individuals PLoS ONE, 2017;12(7):e0181464. 2017 [PMID: 28723950] (Bioassay, Human)
• Marroquin Belaunzaran O, Kleber S, Schauer S, Hausmann M, Nicholls F, van den Broek M, Payeli S, Ciurea A, Milling S, Stenner F, Shaw J, Kollnberger S, Bowness P, Petrausch U, Renner C HLA-B27-Homodimer-Specific Antibody Modulates the Expansion of Pro-Inflammatory T-Cells in HLA-B27 Transgenic Rats. PLoS ONE, 2015;10(6):e0130811. 2015 [PMID: 26125554] (Bioassay, Human)

Bioinformatics

• Gene Symbol: KIR3DL2
• Uniprot:
  • P43630()